Balfour D J
Department of Psychiatry, University of Dundee Medical School, Ninewells Hospital, Dundee DD1 9SY, UK.
Int J Clin Pract. 2001 Jan-Feb;55(1):53-7.
Tobacco dependence remains the major preventable cause of early mortality and morbidity in the developed world. The primary reinforcer of the dependence is the nicotine present in tobacco smoke and, for many smokers, successful treatment depends upon breaking this dependence. Until recently, the only specific pharmacotherapy available for tobacco dependence was nicotine replacement therapy (NRT). Although this approach does significantly increase long-term cessation rates, it is by no means a panacea for the many smokers who require help to quit. Recently, a new drug, bupropion (Zyban), has been licensed as an additional pharmacological aid for smoking cessation. This commentary discusses the mechanisms that may account for its efficacy in this indication and considers the impact its introduction may have on the approach of healthcare systems to the treatment of tobacco dependence.
在发达国家，烟草依赖仍然是可预防的导致过早死亡和发病的主要原因。这种依赖的主要强化物是烟草烟雾中的尼古丁，对许多吸烟者来说，成功戒烟取决于打破这种依赖。直到最近，唯一可用于治疗烟草依赖的特定药物疗法是尼古丁替代疗法（NRT）。尽管这种方法确实能显著提高长期戒烟率，但对于许多需要帮助戒烟的吸烟者来说，它绝不是万灵药。最近，一种新药安非他酮（Zyban）已获许可作为戒烟的辅助药物。本评论讨论了可能解释其在该适应症中疗效的机制，并考虑了其引入可能对医疗系统治疗烟草依赖方法产生的影响。
